References
- Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior. J Reprod Med 1988;33:340–346.
- Singh BB, Berman BM, Simpson RL, Annchild A. Incidence of premenstrual symptome and remedy usage: a national probability sample study. Altern Ther Health Med 1998;4:75–79.
- Zhao G, Wang L, Qu C. Prevalence of premenstrual syndrome in reproductive women and its influential factors. Clin J Obstet Gynecol 1998;33:222–224.
- Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines of management. J Psychiatry Neurosci 2000;45:459–468.
- Qiao M, Zhang Z, Xu X, Han X, Ci Y, Ye Q. Epidemiological survey on syndromes distribution in PMS. Chin J Basic Med Traditional Chin Med 1997;3:31–33.
- Keye WR Jr. General evaluation of premenstrual symptoms. Clin Obstet Gynecol 1987;30:396–407.
- Mortola JF. Issues in the diagnosis and research of premenstrual syndrome. Clin Obstet Gynecol 1992;35:587–598.
- Ramcharan S, Love EJ, Fick GH, Goldfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: attributable risk and risk factors. J Clin Epidemiol 1992;45:377–392.
- Angst J, Sellaro R, Merikangas KR, Endicott J. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001;104:110–116.
- Taylor JW. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr Scand 1979;60:76–86.
- Seippel L, Eriksson O, Grankvist K, von Shoultz B, Backstrom T. Physical symptoms in premenstrual syndrome are related to plasma progesterone and desoxycorticosterone. Gynecol Endocrinol 2000;14:173–181.
- Ellen WF, Karl R, Steven JS, Marcia P. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder. Arch Gen Psychiatry 1999;56:932–939.
- Ellen WF, Jabara S, Steven JS, Roxellen A. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 2002;11:459–464.
- Ho KY, Thorner MO. Therapeutic applications of bromcriptine in endocrine and neurological diseases. Drugs 1988;36:67–82.
- Wuttke W, Gorkow C, Jarry H. Dopaminergic compounds in Vitex agnus castus. In: Loew RN, Darmstadt D, editors. Phytopharmaka in Foschung und klinischer Anwendung: Steinkopff Verlag; 1995. pp 81–91.
- KiIicdag EB, Tarim E, Bagis T, Erkanli S, Aslan E, Ozsahin K, Kuscu E. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia. Int J Gynaecol Obstet 2004;85:292–293.
- Halaska M, Beles P, Gorkow C, Sieder C. Treatment of ciclical mastalgia with a solution containing a Vitex agnus castus extract: results of a placebo-controlled double-blind study. Breast 1999;8:175–181.
- Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol Clin Exp 2003;18:191–195.
- Lauritzen Ch, Reuter HD, Repges R, B¨ohnert KJ, Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus. Controlled, double-blind study vs. pyridoxine. Phytomedicine 1997;4:183–189.
- Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective,randomised, placebo controlled study. BMJ 2001;322:134–137.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision ed. Washington: American Psychiatric Association; 2000. pp. 771–774.
- Steiner M, Haskett RF, Carroll BJ. Premenstrual syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980;62:177–190.
- Thys-Jaccobs S, Alvir J, Fratarcangelo P. Assessment and rating instrument: comparative analysis of three PMS assessment instruments- the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 1995;31:389–396.